Biotech Heron Therapeutics announced last week that the FDA had approved its drug Aponvie (aprepitant), for the prevention of postoperative nausea and vomiting (PONV).
Aponvie became the first and only IV formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of PONV.
The approval hinged on results from two multi-center, randomized, double-blind clinical studies comparing that measured the efficacy of the IV formulation of aprepitant against the current standard of care and found that treatment with Aponvie resulted in fewer patients vomiting.